Advertisement

Topics

FDA Approves Celgene’s Oral Targeted Therapy Idhifa for Treatment of Relapsed/Refractory AML and an IDH2 Mutation

09:30 EDT 2 Aug 2017 | Speciality Pharma Journal

SUMMIT, N.J., & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Celgene Corporation (NASDAQ:CELG) and Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) today announced that IDHIFA® (enasidenib) was granted approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory AML (R/R AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA approved test.1 IDHIFA, an …

Original Article: FDA Approves Celgene’s Oral Targeted Therapy Idhifa for Treatment of Relapsed/Refractory AML and an IDH2 Mutation

NEXT ARTICLE

More From BioPortfolio on "FDA Approves Celgene’s Oral Targeted Therapy Idhifa for Treatment of Relapsed/Refractory AML and an IDH2 Mutation"

Quick Search
Advertisement
 

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...